Search

Displaying results 9851 - 9860 of 10000 in total
  1. Drug

    Biomodulin T

    go.drugbank.com/drugs/DB16529
    Experimental

    Biomodulin T is a polypeptide fraction from bovine thymus with immunomodulatory effects.

  2. Drug

    OPB-111077

    go.drugbank.com/drugs/DB16630
    Investigational

    OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. It has demonstrated promising anticancer activity in preclinical models.

  3. Drug

    Imsidolimab

    go.drugbank.com/drugs/DB16658
    Investigational

    Imsidolimab is under investigation in clinical trial NCT03633396 (A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis).

  4. Drug

    Zagotenemab

    go.drugbank.com/drugs/DB16674
    Investigational

    Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease).

  5. Drug

    Ravagalimab

    go.drugbank.com/drugs/DB16676
    Investigational

    Ravagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis

  6. Drug

    Cadonilimab

    go.drugbank.com/drugs/DB16680
    Investigational

    Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

  7. Drug

    Efmitermant alfa

    go.drugbank.com/drugs/DB16686
    Investigational

    Efmitermant alfa, a locally-acting GDF/activin ligand trap, is under investigation in clinical trial NCT03124459 (Study of ACE-083 in Patients With Charcot-marie-tooth Disease).

  8. Drug

    Tengonermin

    go.drugbank.com/drugs/DB16689
    Investigational

    Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. … [A233270] Literature demonstrates that NGR-peptides bind to a CD13 isoform, of which expression is restricted to tumor vasculature cells.

  9. Drug

    Glutazumab

    go.drugbank.com/drugs/DB16697
    Experimental

    Glutazumab is a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein exerting anti-diabetic effects.[A235745]

  10. Drug

    Neihulizumab

    go.drugbank.com/drugs/DB16698
    Investigational

    Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.[L34450]